- Home
- ESPR vs PRQR Comparison
ESPR vs PRQR Comparison
Compare ESPR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- PRQR
- Stock Information
- Founded
- ESPR 2008
- PRQR 2012
- Country
- ESPR United States
- PRQR Netherlands
- Employees
- ESPR N/A
- PRQR N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- PRQR Health Care
- Exchange
- ESPR Nasdaq
- PRQR Nasdaq
- Market Cap
- ESPR 202.2M
- PRQR 179.1M
- IPO Year
- ESPR 2013
- PRQR 2014
- Fundamental
- Price
- ESPR $1.20
- PRQR $2.35
- Analyst Decision
- ESPR Buy
- PRQR Strong Buy
- Analyst Count
- ESPR 6
- PRQR 8
- Target Price
- ESPR $6.50
- PRQR $8.88
- AVG Volume (30 Days)
- ESPR 3.1M
- PRQR 365.1K
- Earning Date
- ESPR 08-11-2025
- PRQR 08-07-2025
- Dividend Yield
- ESPR N/A
- PRQR N/A
- EPS Growth
- ESPR N/A
- PRQR N/A
- EPS
- ESPR N/A
- PRQR N/A
- Revenue
- ESPR $259,574,000.00
- PRQR $21,212,711.00
- Revenue This Year
- ESPR $4.07
- PRQR N/A
- Revenue Next Year
- ESPR N/A
- PRQR N/A
- P/E Ratio
- ESPR N/A
- PRQR N/A
- Revenue Growth
- ESPR 12.99
- PRQR 85.91
- 52 Week Low
- ESPR $0.69
- PRQR $1.07
- 52 Week High
- ESPR $3.94
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ESPR 63.86
- PRQR 66.90
- Support Level
- ESPR $1.10
- PRQR $2.10
- Resistance Level
- ESPR $1.26
- PRQR $2.18
- Average True Range (ATR)
- ESPR 0.08
- PRQR 0.13
- MACD
- ESPR 0.02
- PRQR 0.01
- Stochastic Oscillator
- ESPR 93.55
- PRQR 56.92
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.